NIBR-17

CAS No. 944396-88-7

NIBR-17( —— )

Catalog No. M27568 CAS No. 944396-88-7

NIBR-17 is a pan class I PI3K inhibitor. NIBR-17 inhibits PI3KKα, PI3KKβ, PI3KKγ, and PI3KKδ with IC50 of 1 nM, 9.2 nM, 9 nM, and 20 nM respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 352 Get Quote
10MG 524 Get Quote
25MG 839 Get Quote
50MG 1143 Get Quote
100MG 1521 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    NIBR-17
  • Note
    Research use only, not for human use.
  • Brief Description
    NIBR-17 is a pan class I PI3K inhibitor. NIBR-17 inhibits PI3KKα, PI3KKβ, PI3KKγ, and PI3KKδ with IC50 of 1 nM, 9.2 nM, 9 nM, and 20 nM respectively.
  • Description
    NIBR-17 is a pan class I PI3K inhibitor. NIBR-17 inhibits PI3KKα, PI3KKβ, PI3KKγ, and PI3KKδ with IC50 of 1 nM, 9.2 nM, 9 nM, and 20 nM respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    DEPTOR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    944396-88-7
  • Formula Weight
    380.4
  • Molecular Formula
    C18H20N8O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COc(cc1)ncc1Nc1cc(-c2cnc(N)nc2)nc(N2CCOCC2)n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Hou Y, et al. Design, Synthesis, and Biological Evaluation of Icaritin Derivatives as Novel Putative DEPTOR Inhibitors for Multiple Myeloma Treatment. J Med Chem. 2021 Oct 28;64(20):14942-14954.
molnova catalog
related products
  • AMG319

    AMG319 (AMG-319) is a potent and selective PI3Kδ inhibitor with biochemical IC50 of 18 nM.

  • PQR514

    PQR514 is a potent PI3K inhibitor with anticancer activity and inhibits cancer cell proliferation.

  • THZ-P1-2

    THZ-P1-2 is a selective and potent PI5P4K inhibitor with anti-leukemic activity that acts by disrupting mitochondrial homeostasis and autophagy.